ProQR Therapeutics develops RNA therapies for severe rare and common diseases using its Axiomer platform for RNA base editing. The platform enables precise single base changes in RNA by recruiting the cell's endogenous ADAR enzymes to correct mutations or modulate protein levels. Based in the Netherlands, the company focuses on genetic disorders with high unmet medical need through this novel oligonucleotide technology.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 3.8 | — | -12.2 | — |
| Q3 2025 | 2.9 | — | -11 | — |
| Q4 2025 | 4.7 | — | -8.9 | — |
| Q1 2026 | 2 | — | -13.4 | — |
| Q2 2026 | 8.8 | 129.5% | -8.7 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Crown Reserve Acquisition Corp. I (CRAC), Alliance Entertainment Holding Corporation (AENT), BitFuFu Inc. (FUFU), UTime Limited (FXHO), High Tide Inc. (HITI), Long Table Growth Corp. (LTGR)